Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $44.71 Average Price Target from Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given an average rating of “Buy” by the ten ratings firms that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $44.71.

Several research analysts have recently weighed in on DNTH shares. Lifesci Capital raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Wedbush lowered their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald assumed coverage on shares of Dianthus Therapeutics in a research report on Thursday, June 27th. They issued an “overweight” rating on the stock. Finally, Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price on the stock.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DNTH. Bain Capital Life Sciences Investors LLC purchased a new stake in Dianthus Therapeutics during the first quarter worth about $89,761,000. RA Capital Management L.P. purchased a new stake in shares of Dianthus Therapeutics during the first quarter worth approximately $69,990,000. Vanguard Group Inc. increased its stake in shares of Dianthus Therapeutics by 250.0% during the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after buying an additional 384,182 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of Dianthus Therapeutics during the first quarter worth approximately $11,251,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $1,404,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Down 0.4 %

Shares of DNTH opened at $28.00 on Wednesday. Dianthus Therapeutics has a 52-week low of $6.58 and a 52-week high of $33.77. The firm’s fifty day moving average is $28.00 and its two-hundred day moving average is $26.13. The stock has a market cap of $821.77 million, a PE ratio of -4.80 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The business had revenue of $1.86 million for the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. As a group, research analysts anticipate that Dianthus Therapeutics will post -2.32 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.